Decoding the m6A-miRNA crosstalk in epileptogenesis: From writer-eraser-reader dynamics to RNA-based precision therapeutics
Review paper
DOI:
https://doi.org/10.5599/admet.3591Keywords:
Epileptogenesis, m6A-miRNA integration, neuroinflammation, dysregulation, RNA-based therapiesAbstract
Background: Epileptogenesis is a dynamic process characterized by continuous molecular, cellular, and network-level changes that result in persistent hyperexcitable neuronal activity and recurring seizures. While well-known, classical mechanisms (such as neurotransmitter imbalance, synaptic remodelling, neuroinflammation, and ion channel dysfunction) are not as well studied as RNA-based epigenetic regulation as an integrated mechanism. Mechanisms: The roles of N6-methyladenosine (m6A) epitranscriptomic modifications and microRNA (miRNA) mediated posttranscriptional regulation have been thoroughly explored as independent processes, but a systematic overview of the crosstalk between different stages of epileptogenesis (acute insult, latency, and chronic epilepsy) has not been conducted. This is a novel review of an integrative m6A-miRNA regulatory mechanism in which the m6A writer, eraser, and reader proteins (METTL3, METTL14, FTO and ALKBH5) directly regulate the biogenesis and maturation of miRNAs, and miRNAs and, in turn, fine-tune the expression of m6A-containing enzymes, creating a self-reinforcing regulatory loop that contributes to neuroinflammation, synaptic remodelling, oxidative stress, and neuronal dysfunction. Implications: Based on this, we review and combine new dual-pathway therapeutic strategies, such as antiepileptic drugs, modulators of the mTOR pathway, anti-inflammatory compounds, and RNA-based therapies, such as miRNA mimics and antagomirs, which can affect pathways that were not previously synthesized in the epilepsy literature. The use of emerging exosome-based nanocarriers to enhance blood-brain barrier penetration for such RNA-based cargo is additionally highlighted. Conclusion: This review, which combines mechanistic and translational approaches, provides a new conceptual framework for the discovery of disease-modifying biomarkers and targets, and for the rethinking of epileptogenesis as a result of an interconnected epitranscriptomic network instead of a series of isolated molecular events.
Downloads
References
[1] A. Pitkänen, J. Engel, Jr. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics 11 (2014) 231-241. https://doi.org/10.1007/s13311-014-0257-2 DOI: https://doi.org/10.1007/s13311-014-0257-2
[2] W.A. Alsharafi, B. Xiao, M.M. Abuhamed, Z. Luo. miRNAs: biological and clinical determinants in epilepsy. Frontiers in Molecular Neuroscience 8 (2015) 59. https://doi.org/10.3389/fnmol.2015.00059 DOI: https://doi.org/10.3389/fnmol.2015.00059
[3] M. Barker-Haliski, H.S. White. Glutamatergic Mechanisms Associated with Seizures and Epilepsy. Cold Spring Harbor Perspective in Medicine 5 (2015) a022863. https://doi.org/10.1101/cshperspect.a022863 DOI: https://doi.org/10.1101/cshperspect.a022863
[4] D. Bojovic, A. Dagostin, S.J. Sullivan, B. Emery, H. von Gersdorff, A. Mishra. Astrocyte gap junctions and K (ir) channels contribute to K(+) buffering and regulate neuronal excitability. Frontiers in Cell Neuroscience 19 (2025) 1571218. https://doi.org/10.3389/fncel.2025.1571218 DOI: https://doi.org/10.3389/fncel.2025.1571218
[5] L. Chen, Y. Wang, Z. Chen. Adult Neurogenesis in Epileptogenesis: An Update for Preclinical Finding and Potential Clinical Translation. Current Neuropharmacology 18 (2020) 464-484. https://doi.org/10.2174/1570159x17666191118142314 DOI: https://doi.org/10.2174/1570159X17666191118142314
[6] S. Chen, D. Xu, L. Fan, Z. Fang, X. Wang, M. Li. Roles of N-Methyl-D-Aspartate Receptors (NMDARs) in Epi¬lepsy. Frontiers in Molecular Neuroscience 14 (2021) 797253. https://doi.org/10.3389/fnmol.2021.797253 DOI: https://doi.org/10.3389/fnmol.2021.797253
[7] T.S. Chen, T.H. Huang, M.C. Lai, C.W. Huang. The Role of Glutamate Receptors in Epilepsy. Biomedicines 11 (2023) 783. https://doi.org/10.3390/biomedicines11030783 DOI: https://doi.org/10.3390/biomedicines11030783
[8] Y. Chen, X. He, Q. Sun, Z. Fang, L. Zhou. Effect of lamotrigine on seizure development in a rat pentylenetetrazole kindling model. Brain and Behavior 7 (2017) e00727. https://doi.org/10.1002/brb3.727 DOI: https://doi.org/10.1002/brb3.727
[9] R.J. Delorenzo, D.A. Sun, L.S. Deshpande. Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy. Pharmacology & Therapeutics 105 (2005) 229-266. https://doi.org/10.1016/j.pharmthera.2004.10.004 DOI: https://doi.org/10.1016/j.pharmthera.2004.10.004
[10] M. Du, J. Li, R. Wang, Y. Wu. The influence of potassium concentration on epileptic seizures in a coupled neuronal model in the hippocampus. Cognitive Neurodynamics 10 (2016) 405-414. https://doi.org/10.1007/s11571-016-9390-4 DOI: https://doi.org/10.1007/s11571-016-9390-4
[11] D.I. Kaplan, L.L. Isom, S. Petrou. Role of Sodium Channels in Epilepsy. Cold Spring Harbor Perspective in Medicine 6 (2016). https://doi.org/10.1101/cshperspect.a022814 DOI: https://doi.org/10.1101/cshperspect.a022814
[12] M. Maqbool, Y. Khan, M.M. Arab, S.O. Alshammari, M.S. Hussain, F.M. Almufarriji. m6A methylation: a new frontier in epilepsy research and therapeutics. Excli Journal 24 (2025) 578-611. https://doi.org/10.17179/excli2025-8359
[13] J. Wang, J. Zhao. MicroRNA Dysregulation in Epilepsy: From Pathogenetic Involvement to Diagnostic Biomarker and Therapeutic Agent Development. Frontiers in Molecular Neuroscience 14 (2021) 650372. https://doi.org/10.3389/fnmol.2021.650372 DOI: https://doi.org/10.3389/fnmol.2021.650372
[14] S.N. Rakhade, F.E. Jensen. Epileptogenesis in the immature brain: emerging mechanisms. Nature Reviews Neurology 5 (2009) 380-391. https://doi.org/10.1038/nrneurol.2009.80 DOI: https://doi.org/10.1038/nrneurol.2009.80
[15] S. Sarfraz, A. Shafqat, S. Muhammad, S.M.M. Anjum, S. Nazir, M. Shoukat. Mechanisms behind epileptogenesis: a comprehensive review. The Research of Medical Science Review 3 (2025) 418-428. https://doi.org/10.5281/zenodo.17394556 DOI: https://doi.org/10.20944/preprints202506.1207.v1
[16] J. Gonzalez, D.M. Villarreal, I.S. Morales, B.E. Derrick. Long-term Potentiation at Temporoammonic Path-CA1 Synapses in Freely Moving Rats. Front Neural Circuits 10 (2016) 2. https://doi.org/10.3389/fncir.2016.00002 DOI: https://doi.org/10.3389/fncir.2016.00002
[17] T.Y. Postnikova, G.P. Diespirov, S.L. Malkin, A.S. Chernyshev, E.N. Vylekzhanina, A.V. Zaitsev. Morphological and Functional Alterations in the CA1 Pyramidal Neurons of the Rat Hippocampus in the Chronic Phase of the Lithium-Pilocarpine Model of Epilepsy. International Journal of Molecular Sciences 25 (2024) 7568. https://doi.org/10.3390/ijms25147568 DOI: https://doi.org/10.3390/ijms25147568
[18] L.A. Marin-Castañeda, G. Pacheco Aispuro, G. Gonzalez-Garibay, C.A. Martínez Zamora, H. Romo-Parra, M. Rubio-Osornio, C. Rubio. Interplay of epilepsy and long-term potentiation: implications for memory. Frontiers in Neuroscience 18 (2024) 1451740. https://doi.org/10.3389/fnins.2024.1451740 DOI: https://doi.org/10.3389/fnins.2024.1451740
[19] O.C. González, I. Timofeev, M. Bazhenov, Role of Ion Concentration Dynamics in Epileptic Seizures, in Jasper's Basic Mechanisms of the Epilepsies, J.L. Noebels, M. Avoli, M.A. Rogawski, A. Vezzani, A.V. Delgado-Escueta, Eds., Oxford University Press, New York, 2024, p. 351-364. https://doi.org/10.1093/med/9780197549469.003.0017 DOI: https://doi.org/10.1093/med/9780197549469.003.0017
[20] J.H. Xu, F.R. Tang. Voltage-Dependent Calcium Channels, Calcium Binding Proteins, and Their Interaction in the Pathological Process of Epilepsy. International Journal of Molecular Sciences 19 (2018) 2735. https://doi.org/10.3390/ijms19092735 DOI: https://doi.org/10.3390/ijms19092735
[21] E. Suleymanova, A. Karan. The Role of Blood–Brain Barrier Disruption in Epilepsy: Mechanisms and Consequences. Neurology International 18 (2026) 1. https://www.mdpi.com/2035-8377/18/1/1 DOI: https://doi.org/10.3390/neurolint18010001
[22] I. Mukhtar. Inflammatory and immune mechanisms underlying epileptogenesis and epilepsy: From pathogenesis to treatment target. Seizure 82 (2020) 65-79. https://doi.org/10.1016/j.seizure.2020.09.015 DOI: https://doi.org/10.1016/j.seizure.2020.09.015
[23] A. Vega García, M.L. López-Meraz, M.I. González, L. Rocha, J.E. Peixoto-Santos, E.A. Cavalheiro. Immunity and neuroinflammation in early stages of life and epilepsy. Epilepsia 66 (2025) 2157-2169. https://doi.org/10.1111/epi.18361 DOI: https://doi.org/10.1111/epi.18361
[24] J. Flammer, T. Neziraj, S. Rüegg, A.K. Pröbstel. Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes. Drugs 83 (2023) 135-158. https://doi.org/10.1007/s40265-022-01826-9 DOI: https://doi.org/10.1007/s40265-022-01826-9
[25] K.T. Sumadewi, S. Harkitasari, D.C. Tjandra. Biomolecular mechanisms of epileptic seizures and epilepsy: a review. Acta Epileptologica 5 (2023) 28. https://doi.org/10.1186/s42494-023-00137-0 DOI: https://doi.org/10.1186/s42494-023-00137-0
[26] A. Vezzani, A. Friedman, R.J. Dingledine. The role of inflammation in epileptogenesis. Neuropharmacology 69 (2013) 16-24. https://doi.org/10.1016/j.neuropharm.2012.04.004 DOI: https://doi.org/10.1016/j.neuropharm.2012.04.004
[27] Y. Chen, M.M. Nagib, N. Yasmen, M.N. Sluter, T.L. Littlejohn, Y. Yu, J. Jiang. Neuroinflammatory mediators in acquired epilepsy: an update. Inflammation Research 72 (2023) 683-701. https://doi.org/10.1007/s00011-023-01700-8 DOI: https://doi.org/10.1007/s00011-023-01700-8
[28] T. Fabisiak, M. Patel. Crosstalk between neuroinflammation and oxidative stress in epilepsy. Frontiers in Cell Developmental Biology 10 (2022) 976953. https://doi.org/10.3389/fcell.2022.976953 DOI: https://doi.org/10.3389/fcell.2022.976953
[29] S. Li, A. Adamu, Y. Ye, F. Gao, R. Mi, G. Xue, Z. Wang. (+)-Borneol inhibits neuroinflammation and M1 phenotype polarization of microglia in epileptogenesis through the TLR4-NFκB signaling pathway. Frontiers in Neuroscience 18 (2024) 1497102. https://doi.org/10.3389/fnins.2024.1497102 DOI: https://doi.org/10.3389/fnins.2024.1497102
[30] S. Guo, H. Wang, Y. Yin. Microglia Polarization From M1 to M2 in Neurodegenerative Diseases. Frontiers Aging Neuroscience 14 (2022) 815347. https://doi.org/10.3389/fnagi.2022.815347 DOI: https://doi.org/10.3389/fnagi.2022.815347
[31] W. Li, J. Wu, Y. Zeng, W. Zheng. Neuroinflammation in epileptogenesis: from pathophysiology to therapeutic strategies. Frontiers in Immunology 14 (2023) 1269241. https://doi.org/10.3389/fimmu.2023.1269241 DOI: https://doi.org/10.3389/fimmu.2023.1269241
[32] X. Liu, Q. Sun, Z. Cao, W. Liu, H. Zhang, Z. Xue, J. Zhao, Y. Feng, F. Zhao, J. Wang, X. Wang. Identification of RNA N6-methyladenosine regulation in epilepsy: Significance of the cell death mode, glycometabolism, and drug reactivity. Frontiers in Genetics 13 (2022) 1042543. https://doi.org/10.3389/fgene.2022.1042543 DOI: https://doi.org/10.3389/fgene.2022.1042543
[33] J. Rowles, M. Wong, R. Powers, M. Olsen. FTO, RNA epigenetics and epilepsy. Epigenetics 7 (2012) 1094-1097. https://doi.org/10.4161/epi.21977 DOI: https://doi.org/10.4161/epi.21977
[34] S. Höfler, O. Duss. Interconnections between m(6)A RNA modification, RNA structure, and protein-RNA complex assembly. Life Science Alliance 7 (2024) e202302240. https://doi.org/10.26508/lsa.202302240 DOI: https://doi.org/10.26508/lsa.202302240
[35] G. Wei. RNA m6A modification, signals for degradation or stabilisation? Biochemical Society Transactions 52 (2024) 707-717. https://doi.org/10.1042/bst20230574 DOI: https://doi.org/10.1042/BST20230574
[36] F. Wang, Q. Liao, Z. Qin, J. Li, Q. Wei, M. Li, H. Deng, W. Xiong, M. Tan, M. Zhou. Autophagy: a critical mechanism of N6-methyladenosine modification involved in tumor progression and therapy resistance. Cell Death & Disease 15 (2024) 783. https://doi.org/10.1038/s41419-024-07148-w DOI: https://doi.org/10.1038/s41419-024-07148-w
[37] J. Li, X. Yang, Z. Qi, Y. Sang, Y. Liu, B. Xu, W. Liu, Z. Xu, Y. Deng. The role of mRNA m(6)A methylation in the nervous system. Cell & Bioscience 9 (2019) 66. https://doi.org/10.1186/s13578-019-0330-y DOI: https://doi.org/10.1186/s13578-019-0330-y
[38] Z. Gao, X. Zha, M. Li, X. Xia, S. Wang. Insights into the m(6)A demethylases FTO and ALKBH5 : structural, biological function, and inhibitor development. Cell & Bioscience 14 (2024) 108. https://doi.org/10.1186/s13578-024-01286-6 DOI: https://doi.org/10.1186/s13578-024-01286-6
[39] Q. Sun, J. Zhu, X. Zhao, X. Huang, W. Qu, X. Tang, D. Ma, Q. Shu, X. Li. Mettl3-m(6)A-NPY axis governing neuron-microglia interaction regulates sleep amount of mice. Cell Discovery 11 (2025) 10. https://doi.org/10.1038/s41421-024-00756-y DOI: https://doi.org/10.1038/s41421-024-00756-y
[40] S. Garbo, D. D'Andrea, A. Colantoni, F. Fiorentino, A. Mai, A. Ramos, G.G. Tartaglia, A. Tancredi, M. Tripodi, C. Battistelli. m6A modification inhibits miRNAs' intracellular function, favoring their extracellular export for intercellular communication. Cell Reports 43 (2024) 114369. https://doi.org/10.1016/j.celrep.2024.114369 DOI: https://doi.org/10.1016/j.celrep.2024.114369
[41] A.K. Chokkalla, S.L. Mehta, R. Vemuganti. Epitranscriptomic regulation by m(6)A RNA methylation in brain development and diseases. Journal of Cerebral Blood Flow & Metabolism 40 (2020) 2331-2349. https://doi.org/10.1177/0271678x20960033 DOI: https://doi.org/10.1177/0271678X20960033
[42] Y. Yao, P. Liu, Y. Li, W. Wang, H. Jia, Y. Bai, Z. Yuan, Z. Yang. Regulatory role of m(6)A epitranscriptomic modifications in normal development and congenital malformations during embryogenesis. Biomedicine & Pharmacotherapy 173 (2024) 116171. https://doi.org/10.1016/j.biopha.2024.116171 DOI: https://doi.org/10.1016/j.biopha.2024.116171
[43] G. Xie, H. Chen, C. He, S. Hu, X. Xiao, Q. Luo. The dysregulation of miRNAs in epilepsy and their regulatory role in inflammation and apoptosis. Functional & Integrative Genomics 23 (2023) 287. https://doi.org/10.1007/s10142-023-01220-y DOI: https://doi.org/10.1007/s10142-023-01220-y
[44] F. Zakaria, S.A. Yousef, J. AbdelDayem, R. ElGamal, O.Y. Issa, M. Mansour, H. Bastorous, E. Emad, R. Mahgoub. The Role of MicroRNAs in the Pathogenesis and as Biomarkers for Pediatric Epilepsy: A Systematic Review. Molecular Diagnosis & Therapy 29 (2025) 571-589. https://doi.org/10.1007/s40291-025-00791-9 DOI: https://doi.org/10.1007/s40291-025-00791-9
[45] K.A. Kołosowska, G. Schratt, J. Winterer. microRNA-dependent regulation of gene expression in GABAergic interneurons. Frontiers in Cellular Neuroscience 17 (2023) 1188574. https://doi.org/10.3389/fncel.2023.1188574 DOI: https://doi.org/10.3389/fncel.2023.1188574
[46] S.V. Kapplingattu, S. Bhattacharya, Y.K. Adlakha. MiRNAs as major players in brain health and disease: current knowledge and future perspectives. Cell Death Discovery 11 (2025) 7. https://doi.org/10.1038/s41420-024-02283-x DOI: https://doi.org/10.1038/s41420-024-02283-x
[47] J. Kapur. Role of NMDA receptors in the pathophysiology and treatment of status epilepticus. Epilepsia Open 3 (2018) 165-168. https://doi.org/10.1002/epi4.12270 DOI: https://doi.org/10.1002/epi4.12270
[48] S. García-Cerro, A. Gómez-Garrido, G. Garcia, B. Crespo-Facorro, D. Brites. Exploratory Analysis of MicroRNA Alterations in a Neurodevelopmental Mouse Model for Autism Spectrum Disorder and Schizophrenia. International Journal of Molecular Sciences 25 (2024) 2786. https://doi.org/10.3390/ijms25052786 DOI: https://doi.org/10.3390/ijms25052786
[49] Y. Shi, X. Zhao, J. Hsieh, H. Wichterle, S. Impey, S. Banerjee, P. Neveu, K.S. Kosik. MicroRNA regulation of neural stem cells and neurogenesis. Journal of Neuroscience 30 (2010) 14931-14936. https://doi.org/10.1523/jneurosci.4280-10.2010 DOI: https://doi.org/10.1523/JNEUROSCI.4280-10.2010
[50] S. Sonawane, V. Všianský, M. Brázdil. MicroRNA-mediated regulation of neurotransmitter receptors in epilepsy: A systematic review. Epilepsy & Behavior 158 (2024) 109912. https://doi.org/10.1016/j.yebeh.2024.109912 DOI: https://doi.org/10.1016/j.yebeh.2024.109912
[51] Q. Zhang, C. Forster-Gibson, E. Bercovici, A. Bernardo, F. Ding, W. Shen, K. Langer, T. Rex, J.Q. Kang. Epilepsy plus blindness in microdeletion of GABRA1 and GABRG2 in mouse and human. Experimental Neurology 369 (2023) 114537. https://doi.org/10.1016/j.expneurol.2023.114537 DOI: https://doi.org/10.1016/j.expneurol.2023.114537
[52] X. Liu, Y. Liao, X. Wang, D. Zou, C. Luo, C. Jian, Y. Wu. MicroRNA expression profiles in chronic epilepsy rats and neuroprotection from seizures by targeting miR-344a. Neuropsychiatric Disease and Treatment 13 (2017) 2037-2044. https://doi.org/10.2147/ndt.S141062 DOI: https://doi.org/10.2147/NDT.S141062
[53] M. Stampanoni Bassi, E. Iezzi, L. Gilio, D. Centonze, F. Buttari. Synaptic Plasticity Shapes Brain Connectivity: Implications for Network Topology. International Journal of Molecular Sciences 20 (2019) 6193. https://doi.org/10.3390/ijms20246193 DOI: https://doi.org/10.3390/ijms20246193
[54] J. Yuan, H. Huang, X. Zhou, X. Liu, S. Ou, T. Xu, R. Li, L. Ma, Y. Chen. MicroRNA-132 Interact with p250GAP/Cdc42 Pathway in the Hippocampal Neuronal Culture Model of Acquired Epilepsy and Associated with Epileptogenesis Process. Neural Plasticity 2016 (2016) 5108489. https://doi.org/10.1155/2016/5108489 DOI: https://doi.org/10.1155/2016/5108489
[55] J. O'Brien, H. Hayder, Y. Zayed, C. Peng. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Frontiers in Endocrinology (Lausanne) 9 (2018) 402. https://doi.org/10.3389/fendo.2018.00402 DOI: https://doi.org/10.3389/fendo.2018.00402
[56] L.P. Liang, S. Waldbaum, S. Rowley, T.T. Huang, B.J. Day, M. Patel. Mitochondrial oxidative stress and epilepsy in SOD2 deficient mice: attenuation by a lipophilic metalloporphyrin. Neurobiology of Disease 45 (2012) 1068-1076. https://doi.org/10.1016/j.nbd.2011.12.025 DOI: https://doi.org/10.1016/j.nbd.2011.12.025
[57] C.R. Reschke, L.F.A. Silva, V.R. Vangoor, M. Rosso, B. David, B.L. Cavanagh, N.M.C. Connolly, G.P. Brennan, A. Sanz-Rodriguez, C. Mooney, A. Batool, C. Greene, M. Brennan, R.M. Conroy, T. Rüber, J.H.M. Prehn, M. Campbell, R.J. Pasterkamp, D.C. Henshall. Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy. Molecular Therapy 29 (2021) 2041-2052. https://doi.org/10.1016/j.ymthe.2021.02.021 DOI: https://doi.org/10.1016/j.ymthe.2021.02.021
[58] D. Tiwari, K. Peariso, C. Gross. MicroRNA-induced silencing in epilepsy: Opportunities and challenges for clinical application. Developmental Dynamics 247 (2018) 94-110. https://doi.org/10.1002/dvdy.24582 DOI: https://doi.org/10.1002/dvdy.24582
[59] S.H. Rastegar-Moghaddam, A. Ebrahimzadeh-Bideskan, S. Shahba, A.M. Malvandi, A. Mohammadipour. Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target. Cellular and Molecular Neurobiology 43 (2023) 455-467. https://doi.org/10.1007/s10571-022-01200-z DOI: https://doi.org/10.1007/s10571-022-01200-z
[60] S. Ghafouri-Fard, B.M. Hussen, A. Abak, M. Taheri, R. Jalili Khoshnoud. Aberrant expression of miRNAs in epilepsy. Molecular Biology Reports 49 (2022) 5057-5074. https://doi.org/10.1007/s11033-022-07188-5 DOI: https://doi.org/10.1007/s11033-022-07188-5
[61] K.D. Yakovleva, D.V. Dmitrenko, I.S. Panina, A.A. Usoltseva, K.A. Gazenkampf, O.V. Konovalenko, E.A. Kantimirova, M.A. Novitsky, R.F. Nasyrova, N.A. Shnayder. Expression Profile of miRs in Mesial Temporal Lobe Epilepsy: Systematic Review. International Journal of Molecular Sciences 23 (2022). https://doi.org/10.3390/ijms23020951 DOI: https://doi.org/10.3390/ijms23020951
[62] M.U. Ashhab, A. Omran, H. Kong, N. Gan, F. He, J. Peng, F. Yin. Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. Journal of Molecular Neuroscience 51 (2013) 950-958. https://doi.org/10.1007/s12031-013-0013-9 DOI: https://doi.org/10.1007/s12031-013-0013-9
[63] J. Wang, J.T. Yu, L. Tan, Y. Tian, J. Ma, C.C. Tan, H.F. Wang, Y. Liu, M.S. Tan, T. Jiang, L. Tan. Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy. Scientific Reports 5 (2015) 9522. https://doi.org/10.1038/srep09522 DOI: https://doi.org/10.1038/srep09522
[64] J. Wang, L. Tan, L. Tan, Y. Tian, J. Ma, C.C. Tan, H.F. Wang, Y. Liu, M.S. Tan, T. Jiang, J.T. Yu. Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy. Scientific Reports 5 (2015) 10201. https://doi.org/10.1038/srep10201 DOI: https://doi.org/10.1038/srep10201
[65] S.H. Avansini, B.P. de Sousa Lima, R. Secolin, M.L. Santos, A.C. Coan, A.S. Vieira, F.R. Torres, B.S. Carvalho, M.K. Alvim, M.E. Morita, C.L. Yasuda, L.R. Pimentel-Silva, D.B. Dogini, F. Rogerio, F. Cendes, I. Lopes-Cendes. MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy. PLoS One 12 (2017) e0173060. https://doi.org/10.1371/journal.pone.0173060 DOI: https://doi.org/10.1371/journal.pone.0173060
[66] E. Brindley, M. Heiland, C. Mooney, M. Diviney, O. Mamad, T.D.M. Hill, Y. Yan, M.T. Venø, C.R. Reschke, A. Batool, E. Langa, A. Sanz-Rodriguez, J.P. Heller, G. Morris, K. Conboy, J. Kjems, G.P. Brennan, D.C. Henshall. Brain cell-specific origin of circulating microRNA biomarkers in experimental temporal lobe epilepsy. Frontiers in Molecular Neuroscience 16 (2023) 1230942. https://doi.org/10.3389/fnmol.2023.1230942 DOI: https://doi.org/10.3389/fnmol.2023.1230942
[67] C. Cava, S. Sabetian, M. Pagoni, I. Castiglioni. Machine Learning Models and Gene Expression Profiles in Epileptic Samples: A Narrative Review. Applied Sciences 16 (2026) 7797. https://www.mdpi.com/2076-3417/16/15/7797 DOI: https://doi.org/10.3390/app16157797
[68] J. Mathoux, M.-M. Wilson, S. Srinivas, G. Litovskich, L. Villalba Benito, C. Tran, J. Cherakka Kesavan, A. Harnett, T. Auer, A. Sanz Rodríguez, M. Alkhayyat, M. Sullivan, Z. Liu, Y. Huang, A. Lacey, N. Delanty, J. Cryan, F. Brett, M. Farrell, G. Brennan. N6-methyladenosine (m6A) dysregulation contributes to network excitability in temporal lobe epilepsy. JCI Insight 10(14) (2025). https://doi.org/10.1172/jci.insight.188612 DOI: https://doi.org/10.1172/jci.insight.188612
[69] Y.M. Liu, M. Liu, H. Yuan, B. Li. Double-edged role of N6-methyladenosine reader YTH structural domain family protein 2 in neurological disorders: Molecular mechanisms and translational prospects. World Journal of Experimental Medicine 16 (2026) 116383. https://doi.org/10.5493/wjem.v16.i1.116383 DOI: https://doi.org/10.5493/wjem.v16.i1.116383
[70] J.P. Szaflarski, Y. Nazzal, L.E. Dreer. Post-traumatic epilepsy: current and emerging treatment options. Neuropsychiatric Disease and Treatment 10 (2014) 1469-1477. https://doi.org/10.2147/ndt.S50421 DOI: https://doi.org/10.2147/NDT.S50421
[71] J. Meng, W. Luo, N. Zhang, M. Yu, Y. He, C. Chen, H. Shu, L. Yu. Silencing epileptic storms: targeting miRNA-lncRNA crosstalk in astrocytes and microglia to disarm neuroinflammatory triggers. Frontiers in Molecular Neuroscience 18 (2025) 1616804. https://doi.org/10.3389/fnmol.2025.1616804 DOI: https://doi.org/10.3389/fnmol.2025.1616804
[72] Y. Weng, W. Yang, Y. Lai. Epigenetic regulation of post-stroke cognitive impairment by gut microbiota and their metabolites. Frontiers in Cellular and Infection Microbiology 16 (2026) 1774049. https://doi.org/10.3389/fcimb.2026.1774049 DOI: https://doi.org/10.3389/fcimb.2026.1774049
[73] M. García-Domínguez. Neuropathic Pain: Mapping the miRNA Landscape. Noncoding RNA 12 (2026). https://doi.org/10.3390/ncrna12020013 DOI: https://doi.org/10.3390/ncrna12020013
[74] J. Lv, L. Xing, X. Zhong, K. Li, M. Liu, K. Du. Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents. Biomedecine & Pharmacotherapy 162 (2023) 114583. https://doi.org/10.1016/j.biopha.2023.114583 DOI: https://doi.org/10.1016/j.biopha.2023.114583
[75] A. Vezzani, S. Balosso, N.H. Varvel, R. Dingledine, Anti-inflammatory Strategies for Disease Modification: Focus on Therapies Close to Clinical Translation, in Jasper's Basic Mechanisms of the Epilepsies, M.A. Rogawski, J.L. Noebels, M. Avoli, M.A. Rogawski, A. Vezzani, A.V. Delgado-Escueta, Eds., Oxford University Press2024, p. 0 9780197549469. https://doi.org/10.1093/med/9780197549469.003.0074 DOI: https://doi.org/10.1093/med/9780197549469.003.0074
[76] J. Engel, Jr., A. Pitkänen. Biomarkers for epileptogenesis and its treatment. Neuropharmacology 167 (2020) 107735. https://doi.org/10.1016/j.neuropharm.2019.107735 DOI: https://doi.org/10.1016/j.neuropharm.2019.107735
[77] R.S. Alshehri, M.S. Alrawaili, B.M.H. Zawawi, M. Alzahrany, A.H. Habib. Pathophysiology of Status Epilepticus Revisited. International Journal of Molecular Sciences 26 (2025). https://doi.org/10.3390/ijms26157502 DOI: https://doi.org/10.3390/ijms26157502
[78] J.A. French, M. Bebin, M.A. Dichter, J. Engel, Jr., A.L. Hartman, S. Jóźwiak, P. Klein, J. McNamara, Sr., R. Twyman, P. Vespa. Antiepileptogenesis and disease modification: Clinical and regulatory issues. Epilepsia Open 6 (2021) 483-492. https://doi.org/10.1002/epi4.12526 DOI: https://doi.org/10.1002/epi4.12526
[79] E. Serrano, A.M. Kanner. Recent treatment advances and novel therapeutic approaches in epilepsy. F1000Prime Reports 7 (2015) 61. https://doi.org/10.12703/p7-61 DOI: https://doi.org/10.12703/P7-61
[80] Y. Jin, L. Ren, X. Jing, H. Wang. Targeting ferroptosis as novel therapeutic approaches for epilepsy. Frontiers in Pharmacology 14 (2023) 1185071. https://doi.org/10.3389/fphar.2023.1185071 DOI: https://doi.org/10.3389/fphar.2023.1185071
[81] S. Sandouka, T. Shekh-Ahmad. Induction of the Nrf2 Pathway by Sulforaphane Is Neuroprotective in a Rat Temporal Lobe Epilepsy Model. Antioxidants (Basel) 10 (2021). https://doi.org/10.3390/antiox10111702 DOI: https://doi.org/10.3390/antiox10111702
[82] M. Wong. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. Expert Review of Neurotherapeutics 13 (2013) 657-669. https://doi.org/10.1586/ern.13.48 DOI: https://doi.org/10.1586/ern.13.48
[83] W. Zhao, C. Xie, X. Zhang, J. Liu, J. Liu, Z. Xia. Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy. Brain & Behavior 13 (2023) e2995. https://doi.org/10.1002/brb3.2995 DOI: https://doi.org/10.1002/brb3.2995
[84] B.L. Clossen, D.S. Reddy. Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. Biochimia et Biophysica Acta Molecular Basis of Disease 1863 (2017) 1519-1538. https://doi.org/10.1016/j.bbadis.2017.02.003 DOI: https://doi.org/10.1016/j.bbadis.2017.02.003
[85] J. Chen, Y. Gao, N. Liu, D. Hai, W. Wei, Y. Liu, X. Lan, X. Jin, J. Yu, L. Ma. Mechanism of NLRP3 Inflammasome in Epilepsy and Related Therapeutic Agents. Neuroscience 546 (2024) 157-177. https://doi.org/10.1016/j.neuroscience.2024.03.029 DOI: https://doi.org/10.1016/j.neuroscience.2024.03.029
[86] F.C. Tescarollo, D.M. Rombo, L.K. DeLiberto, D.E. Fedele, E. Alharfoush, R. Tomé Â, R.A. Cunha, A.M. Sebastião, D. Boison. Role of Adenosine in Epilepsy and Seizures. Journal of Caffeine and Adenosine Research 10 (2020) 45-60. https://doi.org/10.1089/caff.2019.0022 DOI: https://doi.org/10.1089/caff.2019.0022
[87] T. Li, G. Ren, D.L. Kaplan, D. Boison. Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. Epilepsy Research 84 (2009) 238-241. https://doi.org/10.1016/j.eplepsyres.2009.01.002 DOI: https://doi.org/10.1016/j.eplepsyres.2009.01.002
[88] P. Mishra, S.C. Singh, B. Ramadass. Drug resistant epilepsy and ketogenic diet: A narrative review of mechanisms of action. World Neurosurgery X 22 (2024) 100328. https://doi.org/10.1016/j.wnsx.2024.100328 DOI: https://doi.org/10.1016/j.wnsx.2024.100328
[89] E.M. Jimenez-Mateos, T. Engel, P. Merino-Serrais, R.C. McKiernan, K. Tanaka, G. Mouri, T. Sano, C. O'Tuathaigh, J.L. Waddington, S. Prenter, N. Delanty, M.A. Farrell, D.F. O'Brien, R.M. Conroy, R.L. Stallings, J. DeFelipe, D.C. Henshall. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nature Medicine 18 (2012) 1087-1094. https://doi.org/10.1038/nm.2834 DOI: https://doi.org/10.1038/nm.2834
[90] E.M. Jimenez-Mateos, I. Bray, A. Sanz-Rodriguez, T. Engel, R.C. McKiernan, G. Mouri, K. Tanaka, T. Sano, J.A. Saugstad, R.P. Simon, R.L. Stallings, D.C. Henshall. miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132. American Journal of Pathology 179 (2011) 2519-2532. https://doi.org/10.1016/j.ajpath.2011.07.036 DOI: https://doi.org/10.1016/j.ajpath.2011.07.036
[91] C.R. Reschke, L.F.A. Silva, B.A. Norwood, K. Senthilkumar, G. Morris, A. Sanz-Rodriguez, R.M. Conroy, L. Costard, V. Neubert, S. Bauer, M.A. Farrell, D.F. O'Brien, N. Delanty, S. Schorge, R.J. Pasterkamp, F. Rosenow, D.C. Henshall. Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy. Molecular Therapy - Nucleic Acids 6 (2017) 45-56. https://doi.org/10.1016/j.omtn.2016.11.002 DOI: https://doi.org/10.1016/j.omtn.2016.11.002
[92] A. Campbell, G. Morris, J.P. Heller, E. Langa, E. Brindley, J. Worm, M.A. Jensen, M.T. Miller, D.C. Henshall, C.R. Reschke. Antagomir-mediated suppression of microRNA-134 reduces kainic acid-induced seizures in immature mice. Scientific Reports 11 (2021) 340. https://doi.org/10.1038/s41598-020-79350-7 DOI: https://doi.org/10.1038/s41598-020-79350-7
[93] S. Mao, J. Wu, J. Yan, W. Zhang, F. Zhu. Dysregulation of miR-146a: a causative factor in epilepsy pathogenesis, diagnosis, and prognosis. Frontiers in Neurology 14 (2023) 1094709. https://doi.org/10.3389/fneur.2023.1094709 DOI: https://doi.org/10.3389/fneur.2023.1094709
[94] A. Iyer, E. Zurolo, A. Prabowo, K. Fluiter, W.G. Spliet, P.C. van Rijen, J.A. Gorter, E. Aronica. MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response. PLoS One 7 (2012) e44789. https://doi.org/10.1371/journal.pone.0044789 DOI: https://doi.org/10.1371/journal.pone.0044789
[95] E. Aronica, K. Fluiter, A. Iyer, E. Zurolo, J. Vreijling, E.A. van Vliet, J.C. Baayen, J.A. Gorter. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. European Journal of Neuroscience 31 (2010) 1100-1107. https://doi.org/10.1111/j.1460-9568.2010.07122.x DOI: https://doi.org/10.1111/j.1460-9568.2010.07122.x
[96] A. Omran, J. Peng, C. Zhang, Q.L. Xiang, J. Xue, N. Gan, H. Kong, F. Yin. Interleukin-1β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia 53 (2012) 1215-1224. https://doi.org/10.1111/j.1528-1167.2012.03540.x DOI: https://doi.org/10.1111/j.1528-1167.2012.03540.x
[97] X. Zhou, J. Chen, H. Tao, Y. Cai, L. Huang, H. Zhou, Y. Chen, L. Cui, W. Zhong, K. Li. Intranasal Delivery of miR-155-5p Antagomir Alleviates Acute Seizures Likely by Inhibiting Hippocampal Inflammation. Neuropsychiatric Disease and Treatment 16 (2020) 1295-1307. https://doi.org/10.2147/ndt.S247677 DOI: https://doi.org/10.2147/NDT.S247677
[98] I.C. Wee, M. Przybyla, J. Touma, L.M. Ittner, J. van Eersel. Genetic medicines for epilepsy: unlocking new avenues for seizure control. Frontiers in Bioengineering & Biotechnology 14 (2026) 1768550. https://doi.org/10.3389/fbioe.2026.1768550 DOI: https://doi.org/10.3389/fbioe.2026.1768550
[99] M.C. Walker. State-of-the-art gene therapy in epilepsy. Current Opinion in Neurology 38 (2025) 128-134. https://doi.org/10.1097/wco.0000000000001349 DOI: https://doi.org/10.1097/WCO.0000000000001349
[100] M. Ledri, M. Kokaia. Gene therapy for epilepsy: An emerging, promising approach for a serious neurological disorder. Journal of Internal Medicine 299 (2026) 302-327. https://doi.org/10.1111/joim.70059 DOI: https://doi.org/10.1111/joim.70059
[101] W.A. Catterall. Dravet Syndrome: A Sodium Channel Interneuronopathy. Current Opinion in Physiology 2 (2018) 42-50. https://doi.org/10.1016/j.cophys.2017.12.007 DOI: https://doi.org/10.1016/j.cophys.2017.12.007
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Muhammad Shahzaib Rasheed, Irsa Akbar, Usman Javed, Mubashir Shakeel, Midra Sajid, Azka Sabir, Marva Zafar, Warda Amjad
This work is licensed under a Creative Commons Attribution 4.0 International License.
